Layer‐by‐Layer Deposition of Antigen Peptides on Bifidobacterium for Subintestinal Lymphatic System‐Guided Personalized Tumor Immunotherapy
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867005982297554944 |
|---|---|
| author | Zhu Chen You‐Teng Qin Qian‐Ru Li Jin‐Lian He Xin‐Chen Deng Yun Zhang Hao‐Dong Yang Jun Feng Yun‐Xia Sun Xian‐Zheng Zhang |
| author_facet | Zhu Chen You‐Teng Qin Qian‐Ru Li Jin‐Lian He Xin‐Chen Deng Yun Zhang Hao‐Dong Yang Jun Feng Yun‐Xia Sun Xian‐Zheng Zhang Zhu Chen You‐Teng Qin Qian‐Ru Li Jin‐Lian He Xin‐Chen Deng Yun Zhang Hao‐Dong Yang Jun Feng Yun‐Xia Sun Xian‐Zheng Zhang |
| collection | Wiley Open Access |
| contents | Layer‐by‐Layer Deposition of Antigen Peptides on Bifidobacterium for Subintestinal Lymphatic System‐Guided Personalized Tumor Immunotherapy Zhu Chen You‐Teng Qin Qian‐Ru Li Jin‐Lian He Xin‐Chen Deng Yun Zhang Hao‐Dong Yang Jun Feng Yun‐Xia Sun Xian‐Zheng Zhang Advanced Materials Abstract Gut‐associated lymphoid tissue (GALT) possesses a highly specialized immune system and is rational as a foothold for oral tumor vaccines. Here, a noninvasive oral vaccine (Bif‐OVA‐Ocur) is designed to engage GALT, inducing both intestinal mucosal and systemic immunity for tumor therapeutics. The vaccine uses Bifidobacterium (Bif) as a delivery vehicle for tumor antigen peptides, which are coated with antigen peptides (OVA) and oxidized curdlan (Ocur) in a layer‐by‐layer (LBL) manner. Upon oral administration, Bif‐OVA‐Ocur is efficiently directed to Peyer's patches (PPs) in the intestines and further presented to antigen‐presenting cells (APCs), which then migrate to the mesenteric lymph nodes (MLNs) to evoke specific T cell responses. In mouse models, Bif‐OVA‐Ocur effectively boosts the production of secretory immunoglobin A (SIgA) and promotes a strong mucosal and systemic immune response, leading to significant tumor suppression and resistance to tumor challenges. Importantly, the vaccine shows no systemic toxicity. This approach to harnessing the intestinal mucosal immune system offers valuable insights for the development of other non‐invasive oral vaccines and therapeutic agents. 10.1002/adma.202503571 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1002/adma.202503571 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_adma_202503571 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Layer‐by‐Layer Deposition of Antigen Peptides on Bifidobacterium for Subintestinal Lymphatic System‐Guided Personalized Tumor Immunotherapy Zhu Chen You‐Teng Qin Qian‐Ru Li Jin‐Lian He Xin‐Chen Deng Yun Zhang Hao‐Dong Yang Jun Feng Yun‐Xia Sun Xian‐Zheng Zhang Advanced Materials Layer‐by‐Layer Deposition of Antigen Peptides on Bifidobacterium for Subintestinal Lymphatic System‐Guided Personalized Tumor Immunotherapy Zhu Chen You‐Teng Qin Qian‐Ru Li Jin‐Lian He Xin‐Chen Deng Yun Zhang Hao‐Dong Yang Jun Feng Yun‐Xia Sun Xian‐Zheng Zhang Advanced Materials Abstract Gut‐associated lymphoid tissue (GALT) possesses a highly specialized immune system and is rational as a foothold for oral tumor vaccines. Here, a noninvasive oral vaccine (Bif‐OVA‐Ocur) is designed to engage GALT, inducing both intestinal mucosal and systemic immunity for tumor therapeutics. The vaccine uses Bifidobacterium (Bif) as a delivery vehicle for tumor antigen peptides, which are coated with antigen peptides (OVA) and oxidized curdlan (Ocur) in a layer‐by‐layer (LBL) manner. Upon oral administration, Bif‐OVA‐Ocur is efficiently directed to Peyer's patches (PPs) in the intestines and further presented to antigen‐presenting cells (APCs), which then migrate to the mesenteric lymph nodes (MLNs) to evoke specific T cell responses. In mouse models, Bif‐OVA‐Ocur effectively boosts the production of secretory immunoglobin A (SIgA) and promotes a strong mucosal and systemic immune response, leading to significant tumor suppression and resistance to tumor challenges. Importantly, the vaccine shows no systemic toxicity. This approach to harnessing the intestinal mucosal immune system offers valuable insights for the development of other non‐invasive oral vaccines and therapeutic agents. 10.1002/adma.202503571 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Layer‐by‐Layer Deposition of Antigen Peptides on Bifidobacterium for Subintestinal Lymphatic System‐Guided Personalized Tumor Immunotherapy |
| topic | Advanced Materials |
| url | https://advanced.onlinelibrary.wiley.com/doi/10.1002/adma.202503571 |